Determinants of spontaneous clearance of NG in patients with an NG infection at the pre-enrolment visit: results of the univariable and multivariable logistic regression analyses, NABOGO trial, Amsterdam, the Netherlands, from 18 September 2017 to 5 June 2020
| Univariable logistic regression | Multivariable logistic regression | |||||
| OR | 95% CI | P value | aOR | 95% CI | P value | |
| Time (in days) between T−1 and T0 | 1.07 | 1.02 to 1.12 | 0.004 | 1.06 | 1.01 to 1.12 | 0.011 |
| Demographics | ||||||
| Age, per 10-year increase | 0.91 | 0.69 to 1.19 | 0.477 | |||
| Age (years) | ||||||
| <30 | REF | 0.253 | REF | |||
| 30–39 | 0.60 | 0.30 to 1.20 | 0.68 | 0.33 to 1.40 | 0.297 | |
| ≥40 | 0.64 | 0.32 to 1.29 | 1.04 | 0.46 to 2.35 | 0.933 | |
| Gender identity | ||||||
| Male | REF | 0.055 | ||||
| Female or transgender | 2.55 | 0.98 to 6.65 | ||||
| Ethnicity | ||||||
| Dutch | REF | 0.814 | ||||
| Non-Dutch | 1.07 | 0.59 to 1.96 | ||||
| Highest education level | ||||||
| None/primary/secondary | REF | 0.628 | ||||
| College/university | 1.46 | 0.66 to 3.21 | ||||
| Other | 1.19 | 0.32 to 4.45 | ||||
| Health | ||||||
| HIV status | ||||||
| HIV-negative+no PrEP user | REF | 0.132 | REF | |||
| HIV-negative+PrEP user | 0.47 | 0.22 to 0.98 | 0.53 | 0.24 to 1.16 | 0.101 | |
| HIV-positive | 0.81 | 0.37 to 1.78 | 0.80 | 0.31 to 2.02 | 0.630 | |
| Antibiotic use* | ||||||
| No | REF | 0.723 | ||||
| Yes | 1.17 | 0.50 to 2.72 | ||||
| Location of NG infection | ||||||
| Pharyngeal | REF | 0.151 | REF | |||
| Anal | 0.69 | 0.37 to 1.26 | 0.63 | 0.32 to 1.25 | 0.189 | |
| Vaginal | 1.24 | 0.31 to 4.90 | 0.28 | 0.03 to 2.50 | 0.255 | |
| Urethral | 1.76 | 0.69 to 4.51 | 1.66 | 0.59 to 4.67 | 0.339 | |
| Sexual behaviour | ||||||
| Sexual risk group | ||||||
| MSM | REF | 0.097 | ||||
| MSW, women, TGP | 2.21 | 0.87 to 5.66 | ||||
| Number of sexual partners†‡ | 0.60 | 0.43 to 0.84 | 0.003 | |||
| Number of sexual partners, in tertiles | ||||||
| ≤5 | REF | 0.002 | REF | |||
| 6–15 | 0.29 | 0.14 to 0.58 | 0.28 | 0.13 to 0.59 | 0.001 | |
| ≥16 | 0.48 | 0.24 to 0.94 | 0.55 | 0.25 to 1.20 | 0.135 | |
Time between T−1 and T0, age, gender identity, HIV status, location of NG infection, sexual risk group and number of sexual contacts in the preceding 6 months before T−1 were included in the initial multivariable model before backwards selection.
*In the preceding 3 months before T−1.
†In the preceding 6 months before T−1.
‡OR per (log+1) increase in number of sexual partners.
aOR, adjusted OR; MSM, men who have sex with men; MSW, men who have sex with women; NABOGO, New AntiBiotic treatment Options for uncomplicated Gonorrhoea; NG, Neisseria gonorrhoeae; PrEP, pre-exposure prophylaxis; REF, reference; TGP, transgender people.